Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Cardiovascular & respiratory systems Pharmacy, pharmacology & toxicology
Author, co-author :
Demarche, Sabine ; Université de Liège - ULiège > Département de physique > Département de physique
Schleich, Florence ; Université de Liège - ULiège > Département des sciences de la motricité > Département des sciences de la motricité
HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme
PAULUS, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme
Van Hees, Thierry ; Université de Liège - ULiège > Département de pharmacie > Pharmacie clinique et pharmacie hospitalière
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Language :
English
Title :
Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre
Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-8.
Louis R, Schleich F, Barnes PJ. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012;33:531-41.
Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000;161:1459-64.
Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90.
Jayaram L, Pizzichini E, Lemiere C, et al. Steroid naive eosinophilic asthma: Anti-inflammatory effects of fluticasone and montelukast. Thorax 2005;60:100-5.
Bacci E, Cianchetti S, Ruocco L, et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin Exp Allergy 1998;28:1237-43.
Basyigit I, Yildiz F, Kacar Ozkara S, et al. Effects of different antiasthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology 2004;9:514-20.
Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005;115:720-7.
Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.
Bacci E, Cianchetti S, Bartoli M, et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006;129:565-72.
Currie GP, Syme-Grant NJ, McFarlane LC, et al. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy 2003;58:602-7.
Brightling CE. Clinical applications of induced sputum. Chest 2006;129:1344-8.
Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic cor ticosteroid unresponsive asthma. The Lancet 1999;353:2213-4.
Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62:1043-9.
Godon P, Boulet LP, Malo JL, et al. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002;20:1364-9.
Lemiere C, Tremblay C, FitzGerald M, et al. Effects of a short course of inhaled corticosteroids in noneosinophilic asthmatic subjects. Can Respir J 2011;18:278-82.
Giannini D, Di Franco A, Cianchetti S, et al. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. Clin Exp Allergy 2000;30:1777-84.
Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: To whom do the results of the trials apply? Thorax 2007;62:219-23.
Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the mini asthma quality of life questionnaire. Eur Respir J 1999;14:32-8.
Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
Louis R, Sele J, Henket M, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002;57:907-12.
Demarche SF, Schleich FN, Paulus VA, et al. Asthma control and sputum eosinophils: A longitudinal study in daily practice. J Allergy Clin Immunol Pract 2017;5:1335-43.
Louis R, Godinas L, Schleich F. Induced sputum-towards normal values. In: Loukides S, Kostikas K, Barnes PJ, eds. Non invasive assessment of airways inflammation in asthma and COPD. Greece, Athens: Paschalidis Medical Publications, 2011:113-23.
Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307-17.
Belvisi MG. Regulation of inflammatory cell function by corticosteroids. Proc Am Thorac Soc 2004;1:207-14.
Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-208.
Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-8.
Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-5.
de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:902-7.
Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006;27:908-12.
Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553-8.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360:1715-21.
Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94.
Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014;11:S322-8.
Pavord ID, Shaw DE, Gibson PG, et al. Inflammometry to assess airway diseases. Lancet 2008;372:1017-9.
Louis R, Demarche S. Time for reasoning ICS prescription in obstructive airway diseases. Int J Clin Pract 2014;68:1176-8.
Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids. Chest 2004;126:213-9.
Raissy HH, Kelly HW, Harkins M, et al. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013;187:798-803.
Demarche SF, Schleich FN, Paulus VA, et al. Is it possible to claim or refute sputum eosinophils 3% in asthmatics with sufficient accuracy using biomarkers? Respir Res 2017;18:133.
